Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 741 mg/ml (equivalent: iodine, qty 350 mg/ml) - injection, solution - excipient ingredients: trometamol hydrochloride; trometamol; sodium calcium edetate; sodium hydroxide; hydrochloric acid; water for injections - shelf life: other conditions: protect from secondary x-rays. optiray 350 is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used for intravenous excretary urography.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 678 mg/ml (equivalent: iodine, qty 320 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; sodium hydroxide; water for injections - other conditions: protect from secondary x-rays. optiray is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include cerebral, coronary, peripheral, visceral and renal arteriography, aortography and venography. opitray may be used for intravenous excretory urography. optiray 320 is indicated in children (excluding neonates) for angiocardiography, contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - midazolam, quantity: 1 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - intravenously as an agent for: conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy,coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid. induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be obtained with a narrower dose range and in a shorter period of time. intermittent intravenous administration or continuous infusion for: sedation in intensive care units. intramuscularly for: preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - intravenously as an agent for: conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy,coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid. induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be obtained with a narrower dose range and in a shorter period of time. intermittent intravenous administration or continuous infusion for: sedation in intensive care units. intramuscularly for: preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intravenously as an agent for: conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy,coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid. induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be obtained with a narrower dose range and in a shorter period of time. intermittent intravenous administration or continuous infusion for: sedation in intensive care units. intramuscularly for: preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 741 mg/ml (equivalent: iodine, qty 350 mg/ml) - injection, solution - excipient ingredients: trometamol hydrochloride; trometamol; sodium calcium edetate; sodium hydroxide; hydrochloric acid; water for injections - shelf life: other conditions: protect from secondary x-rays. optiray 350 is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used for intravenous excretary urography.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

guerbet australia pty ltd - ioversol, quantity: 741 mg/ml (equivalent: iodine, qty 350 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; sodium hydroxide; hydrochloric acid; water for injections; trometamol hydrochloride - shelf life: other conditions: protect from secondary x-rays. optiray 350 is indicated in adults for angiography throughout the cardiovascular system by conventional or digital subtraction techniques. these include coronary, peripheral, visceral and renal arteriography, aortography, left ventriculography and venography. optiray may be used for intravenous excretary urography.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nortriptyline, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; hypromellose; glycerol; maize starch; calcium phosphate; sunset yellow fcf aluminium lake - allegron is indicated for the treatment of major depression.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: macrogol 300; citric acid; polysorbate 80; ethanol absolute - indications as at 3 april 1996: etoposide injection is indicated for the following: small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia. hodgkin's disease. non-hodgkin's lymphoma

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. with three episodes in two years, there is no doubt it should be given. as a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. a major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. for these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.